Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
Posted on: Friday, 27 March 2009, 15:43 CDT
SHENZEN,
The MMR Vaccine is a mixture of three live attenuated viruses administered via injection for immunization against measles, mumps, and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5).
Prior to the widespread use of a vaccine against measles, its incidence was so high that infection was felt to be inevitable. Today, it is widely used around the world, and since introduction of its earliest versions in the 1970s, more than 500 million doses have been administered in over 60 countries. The incidence rate has fallen to a low of less than 1% of people under the age of 30 in countries with routine childhood vaccination.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com
SOURCE Hard to Treat Diseases
Source: PR Newswire
Related Articles
- HPV Vaccine By Age 21 is a Sound Investment
- CDC Recommends ZOSTAVAX(R), Merck's Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
- New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
- The Age of Autism: Anna's Last Days -- 1
- Pakistan to Launch Vaccination Campaign in Quake-Hit Areas 19 December
- Flu Vaccine Won't Run Out; Ulster Has 'Adequate Supplies'
- FDA Approves PROQUAD(R), the First and Only Vaccine in the U.S. To Help Protect Children Against Measles, Mumps, Rubella and Chickenpox in One Shot; PROQUAD(R) Combines Two Well-Established Merck Vaccines, M-M-R(R)II and VARIVAX(R)
- FDA Approves Expanded Age Indication for VAQTA(R) (Hepatitis A Vaccine, Inactivated), Merck's Hepatitis A Vaccine, to Children As Young As 12 Months of Age
- Immunization Rate Exceeds Federal Goals
- CDC Panel Recommends Whooping Cough Shots
 |
 |
User Comments (0)
RSS Feeds